Divi's Lab slumps after earnings lag estimates

Reuters Market Eye - Shares of Divi's Laboratories Ltd
The drugmaker's operating margin fell to 35 percent from 39 percent.
Analysts say management's focus has been more on its Vizag unit, which is awaiting an inspection by the U.S. Food and Drug Administration.
(abhishek.vishnoi@thomsonreuters.com / abhishek.vishnoi.thomsonreuters.com@reuters.net)
More From This Section
Don't miss the most important news and views of the day. Get them on our Telegram channel
First Published: May 26 2014 | 12:22 PM IST
